Dialysis Facility Scorecard Measure Specifications - April 2023

Facility Scorecard Definitions:

**Network Measure**: CMS established measure for Networks.

**Network Goal**: CMS established goal for Networks.

**Facility Baseline**: Facility specific count or rate at baseline for each measure.

**Facility Specific Goal**: Facility specific goal calculated by the Network for each measure based on the CMS established goal.

**Facility Remeasurement**: Facility specific rate or count based on February 2023 data.

**Facility Percentile in the Network**: Percentile ranking for the facility for each measure based on February 2023 remeasurement data.

### Measure Specifications Table 1

<table>
<thead>
<tr>
<th>Measure name</th>
<th>Numerator</th>
<th>Denominator</th>
<th>Attribution</th>
<th>Exclusion Criteria</th>
<th>Measure Time Periods</th>
</tr>
</thead>
</table>
| Patients Identified with Depression and Receiving Treatment | Patients in the denominator with a Medicare outpatient claim for depression treatment by a mental health professional. | Patients with depression as identified by one of the checked variables in EQRS of: • Screening for clinical depression is documented as being positive, and a follow-up plan is documented • Screening for clinical depression is documented as being positive, the facility possesses no documentation of a follow-up plan, and no reason is given | Patients are attributed to the facility from which they received dialysis for at least 90 days during measure period | • Patients less than 12 years of age • Patients treated at the dialysis facility for less than 90 days • Patients without positive depression screening reported • Patients with a positive depression screening that indicates the patient is not eligible for follow-up plan • Patients not enrolled in Medicare FFS • Patients without Medicare Part B coverage • Facilities with less than 11 eligible patients during the performance period • Facilities certified April 1 or later during performance year | Baseline: January 1, 2020 – December 31, 2020

Remeasurement: January 1, 2022 – December 31, 2022 |
| Incident Patients Starting Home Dialysis          | Count of Incident dialysis patients whose initial setting in EQRS is home during the performance period. Incident is defined as an admission for one of the following: • New ESRD patient Restart • Dialysis after transplant failed | None                                                                         | Patients are attributed to the facility to whom the incident patient was admitted to | • Transplant facilities • Patients discharged as acute • Facilities that do not have a home dialysis program. | Baseline: January 1, 2020 – December 31, 2020

Remeasurement: May 1, 2022 – February 28, 2023 |
<table>
<thead>
<tr>
<th>Measure name</th>
<th>Numerator</th>
<th>Denominator</th>
<th>Attribution</th>
<th>Exclusion Criteria</th>
<th>Measure Time Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalent Patients Transitioning to Home Dialysis</td>
<td>Patient transitions to a home setting in EQRS during the performance period</td>
<td>None</td>
<td>Patients are attributed to the facility prior to the transition to home setting</td>
<td>• Patients whose only setting during the measurement period is home.</td>
<td>Baseline: January 1, 2020 – December 31, 2020 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td></td>
<td>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with &quot;&lt; 11&quot;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients Added to the Transplant Waitlist</td>
<td>Patients added to a kidney transplant waiting list within the performance period</td>
<td>None</td>
<td>Patients are attributed to the facility the patient was admitted to immediately prior to being added to a kidney transplant waiting list</td>
<td>• Transplant facilities</td>
<td>Baseline: January 1, 2020 – December 31, 2020 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td></td>
<td>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with &quot;&lt; 11&quot;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients Receiving a Kidney Transplant</td>
<td>Patients who received a transplant within the performance period</td>
<td>None</td>
<td>Patients are attributed to the facility the patient was admitted to immediately prior to the transplant</td>
<td>• Transplant facilities</td>
<td>Baseline: January 1, 2020 – December 31, 2020 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td></td>
<td>Due to CMS data requirements, if the count is 1-10, then the cell is blinded with &quot;&lt; 11&quot;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 Hospitalizations per 100 Patient Months</td>
<td>Count of inpatient hospitalizations with a Medicare claim that includes a diagnosis of COVID-19 (ICD-10 U07.1)</td>
<td>The number of patient-months where patients are being treated in a dialysis facility during the performance period.</td>
<td>Patients are attributed to the facility where treatment was received as of the most current treatment record.</td>
<td>• The patient-month is excluded for patients not in enrolled in Medicare fee-for-service (FFS) • Patients attributed to a transplant center</td>
<td>Baseline: June 1, 2020 – April 30, 2021 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td>Measure name</td>
<td>Numerator</td>
<td>Denominator</td>
<td>Attribution</td>
<td>Exclusion Criteria</td>
<td>Measure Time Periods</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>COVID-19 Patient Vaccinations – Initial or Completed Series</td>
<td>Denominator patients that have received a COVID-19 vaccination administration as reported in NHSN</td>
<td>Number of patients receiving dialysis care from this facility as reported to NHSN</td>
<td>Patients are attributed to their point prevalent dialysis facility</td>
<td>• Patients with a medical contraindication to COVID-19 vaccine</td>
<td>Baseline: None, Remeasurement: Most recent NHSN data</td>
</tr>
<tr>
<td>COVID-19 Patient Vaccination Booster</td>
<td>Denominator patients that have received a booster dose of COVID-19 vaccine as reported in NHSN</td>
<td>Total number of patients who have received any completed COVID-19 vaccination series</td>
<td>Patients are attributed to their point prevalent dialysis facility</td>
<td>• Patients with a medical contraindication to COVID-19 vaccine</td>
<td>Baseline: None, Remeasurement: Most recent NHSN data</td>
</tr>
<tr>
<td>COVID-19 Healthcare Personnel (HCP) Vaccinations – Initial or Completed Series</td>
<td>Denominator HCP that have received a COVID-19 vaccination administration as reported in NHSN</td>
<td>Number of all HCP that were eligible to have worked at this healthcare facility for at least one day during the week of data collection as reported to NHSN</td>
<td>HCP are attributed to the facility where they are work.</td>
<td>• HCP with a medical contraindication to COVID-19 vaccine</td>
<td>Baseline: None, Remeasurement: Most recent NHSN data</td>
</tr>
<tr>
<td>COVID-19 Healthcare Personnel (HCP) Vaccination Booster</td>
<td>Denominator HCP that have received a booster dose of COVID-19 vaccine as reported in NHSN</td>
<td>Total number of HCP who have received any completed COVID-19 vaccination series</td>
<td>HCP are attributed to the facility where they are work.</td>
<td>• HCP with a medical contraindication to COVID-19 vaccine</td>
<td>Baseline: None, Remeasurement: Most recent NHSN data</td>
</tr>
<tr>
<td>Influenza Patient Vaccination</td>
<td>Denominator patients with an influenza vaccination administration date from August 2022 through latest available record in EQRS</td>
<td>Patients on dialysis as of the end of the performance period</td>
<td>Patients are attributed to their dialysis facility as of the end of the measurement period</td>
<td>• Patients not receiving dialysis as of end of measurement period. • Patients meeting following criteria will be excluded unless they have an influenza administration date of August 2022 or later reported in EQRS: o Patients with a documented allergic or adverse reaction or other medical reason o Patients that decline for religious or philosophical reasons.</td>
<td>Baseline: None, Remeasurement: Most recent EQRS data</td>
</tr>
<tr>
<td>Measure name</td>
<td>Numerator</td>
<td>Denominator</td>
<td>Attribution</td>
<td>Exclusion Criteria</td>
<td>Measure Time Periods</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Patients receiving pneumococcal conjugate vaccine (PCV) 13 | Number of dialysis patients with a PCV13 vaccination administration date reported in EQRS by the end of the performance period | Patients on dialysis as of the end of the performance period                  | Patients are attributed to their dialysis facility at the end of the performance period | • Patients of not receiving dialysis as of end of measurement period.  
• Patients meeting following criteria will be excluded unless they have a PCV13 administration date reported in EQRS:  
  o Patients with a documented allergic or adverse reaction or other medical reason  
  o Patients that decline for religious or philosophical reasons.  
  o Patients with PCV15 or PCV20 vaccination reported in EQRS  
  o Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS. | Baseline: Records in EQRS indicating PCV vaccination received in 2020 or earlier  
Remeasurement: Records in EQRS indicating PCV vaccination received in 2023 or earlier as of February 2023 |
| Patients Receiving Pneumococcal Polysaccharide Vaccine (PPSV23) - Initial | Denominator patients with a PPSV23 vaccination administration date reported in EQRS | Patients, age 2 years or older, on dialysis as of end of the performance period | Patients are attributed to their dialysis facility at the end of the performance period | • Patients of not receiving dialysis as of end of measurement period.  
• Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:  
  o Patients with a documented allergic or adverse reaction or other medical reason  
  o Patients that decline for religious or philosophical reasons.  
  o Patients with PCV20 vaccination reported in EQRS  
  o Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.  
  o Patients younger than 2 years | Baseline: None  
Remeasurement: Most recent EQRS data as of February 2023 |
<table>
<thead>
<tr>
<th>Measure name</th>
<th>Numerator</th>
<th>Denominator</th>
<th>Attribution</th>
<th>Exclusion Criteria</th>
<th>Measure Time Periods</th>
</tr>
</thead>
</table>
| Patients Receiving a Pneumococcal Polysaccharide Vaccine (PPSV23) - Booster | Denominator patients that have PPSV23 booster vaccination administration date reported in EQRS | Patients on dialysis at the end of the performance period and have received an initial PPSV23 vaccination at least 5 years previously and prior to age 65 | Patients are attributed to their dialysis facility at the end of the performance period | - Patients of not receiving dialysis as of end of measurement period.  
- Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:  
  o Patients with a documented allergic or adverse reaction or other medical reason  
  o Patients that decline for religious or philosophical reasons.  
  o Patients with a PCV15 or PCV20 vaccination reported in EQRS  
  o Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.  
  o Patients who have not received an initial PPSV23 vaccination  
  o Patients who received an initial PPSV23 vaccination within the previous five years  
  o Patients aged 65 or older and received a PPSV23 vaccination | Baseline:  
Any PPSV23 in EQRS indicating 2020 or earlier as year received that is 5 or more years after initial  
Remeasurement:  
Any PPSV 23 in EQRS indicating 2023 or earlier as year received that is 5 or more years after initial as of February 2023 |
| Patients Receiving Pneumococcal Polysaccharide Vaccine (PPSV23) - Age 65 or Older | Denominator patients with a PPSV23 vaccination administration date reported in EQRS | Patients on dialysis at the end of the performance period age 65 or older | Patients are attributed to their dialysis facility at the end of the measurement period | - Patients of not receiving dialysis as of end of measurement period.  
- Patients meeting following criteria will be excluded unless they have a PPSV23 administration date reported in EQRS:  
  o Patients with a documented allergic or adverse reaction or other medical reason  
  o Patients that decline for religious or philosophical reasons.  
  o Patients with a PCV15 or PCV20 vaccination reported in EQRS  
  o Patients with Unknown vaccination and date of January 1, 2022, or later reported in EQRS.  
  o Patients who have not received an initial PPSV23 vaccination  
  o Patients who received an initial PPSV23 vaccination within the previous five years  
  o Patients younger than age 65 | Baseline: None  
Remeasurement: Most recent EQRS data as of February 2023 |
<table>
<thead>
<tr>
<th>Measure name</th>
<th>Numerator</th>
<th>Denominator</th>
<th>Attribution</th>
<th>Exclusion Criteria</th>
<th>Measure Time Periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRD-Related Hospitalizations per 100 Patient Months</td>
<td>Count of ESRD-related inpatient hospital admissions during the performance period with a Medicare claim for primary diagnosis from Appendix A.</td>
<td>The number of patient-months where patients are being treated in a dialysis facility during the performance period.</td>
<td>Patients are attributed to the facility where treatment was received as of the most current treatment record.</td>
<td>The patient-month is excluded for • Patients not in enrolled in Medicare fee-for-service (FFS) • Patients attributed to a transplant center</td>
<td>Baseline: June 1, 2020 – April 30, 2021 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td>Hospital 30-Day Unplanned Readmissions</td>
<td>Count of index admissions with at least one ESRD-related unplanned readmission with the following: • a Medicare claim with a primary diagnosis from Appendix A. • an admission admit within 30 days of discharge from the index admission. • Not a planned visit as defined by the CMS Planned Readmission Algorithm</td>
<td>ESRD-related inpatient admission (index admission) with the following: • Discharge during the performance period • Has a primary diagnosis from Appendix A • Patient is discharged alive. Note that, as with other CMS readmission measures, the denominator is discharges, not patients, and each patient can contribute more than one discharge.</td>
<td>Patients are attributed to the facility where treatment was received as of the most current treatment record.</td>
<td>Discharges are excluded for • Patients not in enrolled in Medicare fee-for-service (FFS) • Patients attributed to a transplant center</td>
<td>Baseline: Index Admission Discharge Date: June 1, 2020 – April 30, 2021 Readmission Adm Date: June 1, 2020 - May 31, 2021 Remeasurement: Index Admission Discharge Date: June 1, 2022 – February 28, 2023 Readmission Adm Date: June 1, 2022 - February 28, 2023</td>
</tr>
<tr>
<td>Outpatient Emergency Department Visits per 100 Patient Months</td>
<td>Count of ESRD-related emergency room treat-and-release visits during the performance period with a Medicare claim with a primary diagnosis from Appendix A.</td>
<td>The number of patient-months where patients are being treated in a dialysis facility during the performance period.</td>
<td>Patients are attributed to the facility where treatment was received as of the most current treatment record.</td>
<td>The patient-month is excluded for • Patients not in enrolled in Medicare fee-for-service (FFS) • Patients attributed to a transplant center</td>
<td>Baseline: June 1, 2020 – April 30, 2021 Remeasurement: May 1, 2022 – February 28, 2023</td>
</tr>
<tr>
<td>Data Quality – Patient Admissions Submitted On Time</td>
<td>Number of admission records in EQRS with an admission record created date within 5 business days of the admission date</td>
<td>Admission records for most recent 12 month period</td>
<td>Patients are attributed to facility admitting patient</td>
<td>• Transplant facilities • Patients discharged as Acute</td>
<td>Baseline: January 1, 2020 – December 31, 2020 Remeasurement: Rolling 12 month period using most recent EQRS data as of February 28, 2023</td>
</tr>
<tr>
<td>Measure name</td>
<td>Numerator</td>
<td>Denominator</td>
<td>Attribution</td>
<td>Exclusion Criteria</td>
<td>Measure Time Periods</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| Data Quality – 2728 Forms Submitted On Time | Number of Initial Dialysis 2728 forms submitted in EQRS with a submitted date within 45 days of the Dialysis at Facility Start Date | Number of Initial Dialysis 2728 forms submitted for most recent 12 month period | Patients are attributed to facility submitting form | • Facility type of Transplant  
• Patients discharged as Acute  
• Patients discharged as Recover Function where discharge date is before form submission date | Baseline: January 1, 2020 – December 31, 2020  
Remeasurement: Rolling 12 month period using most recent EQRS data as of February 28, 2023 |
| Data Quality – 2746 Forms Submitted On Time | Number of 2746 forms submitted in EQRS with a submitted date within 14 days of the death date | Number of 2746 forms submitted for most recent 12 month period | Patients are attributed to facility submitting form | • Facility type of Transplant  
• Patients discharged as Acute  
• Patients discharged as Recover Function where discharge date is before form submission date | Baseline: January 1, 2020 – December 31, 2020  
Remeasurement: Rolling 12 month period using most recent EQRS data as of February 28, 2023 |
Appendix A: List of Priority Diagnosis Categories

- A419 Sepsis, unspecified organism
- E875 Hyperkalemia
- E8770 Fluid overload unspecified
- I214 Non-ST elevation (N STEMI) myocardial infarction
- I120 Hypertensive chronic kidney disease stage 5 or end stage renal disease
- T82868A Thrombosis due to vascular prosthetic devices, implants and grafts, initial encounter
- T82868D Thrombosis due to vascular prosthetic devices, implants and grafts, subsequent encounter
- T82868S Thrombosis due to vascular prosthetic devices, implants and grafts, sequela
- I161 Hypertensive Emergency
- T8571XA Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter
- T8571XD Infection and inflammatory reaction due to peritoneal dialysis catheter, subsequent encounter
- T8571XS Infection and inflammatory reaction due to peritoneal dialysis catheter, sequela
- T80211A Bloodstream infection due to central venous catheter, initial encounter
- T80211D Bloodstream infection due to central venous catheter, subsequent encounter
- T80211S Bloodstream infection due to central venous catheter, sequela
- T82838A Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter
- T82838D Hemorrhage due to vascular prosthetic devices, implants and grafts, subsequent encounter
- T82838S Hemorrhage due to vascular prosthetic devices, implants and grafts, sequela
- E8779 Other fluid overload
- I2510 Atherosclerosis heart disease of native coronary artery without angina pectoris
- J810 Acute pulmonary edema
- A4101 Sepsis due to Methicillin Susceptible Staphylococcus aureus
- A4102 Sepsis due to Methicillin Resistant Staphylococcus aureus
- T82858A Stenosis of other vascular prosthetic devices, implants and grafts, initial encounter
- T82858D Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter
- T82858S Stenosis of other vascular prosthetic devices, implants and grafts, sequela
- R079 Chest pain, unspecified
- D649 Anemia unspecified
- E1110 DM Type 2 with ketoacidosis without coma
- A4181 Sepsis due to Enterococcus
- E1122 Diabetes type 2 with diabetic chronic kidney disease
- I169 Hypertensive Crisis, Unspecified
- E871 Hypo-osmolality and hyponatremia
- E876 Hypokalemia
- E162 Hypoglycemia, unspecified
- A4150 Gram-negative sepsis, unspecified